Table 2.
Subjective clinical efficacy: investigator assessment of outcome at follow-up (ITT population)
| Response, n (%) |
|||
|---|---|---|---|
| delafloxacin (n = 81) | linezolid (n = 77) | vancomycin (n = 98) | |
| Curea | 57 (70.4) | 50 (64.9) | 53 (54.1)b |
| Improved | 11 (13.6) | 13 (16.9) | 26 (26.5) |
| Failure | 5 (6.2) | 3 (3.9) | 7 (7.1) |
| Indeterminate | 8 (9.9) | 11 (14.3) | 12 (12.2) |
aClinical success is defined as investigator assessment of cure only; improved, failure and indeterminate equate to failure.
bP < 0.05 versus delafloxacin, Cochran–Mantel–Haenszel test.